{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032838","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2026-08-13T20:38:45+00:00","discovered_at":"2026-08-13T20:40:00.390458+00:00","generated_at":"2026-08-13T20:40:08.850324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuwellis Q2 net sales up 14% to $2.0M; gross margin 76% vs 56%; CEO appointed","bullets":["Net sales $2.0M, +14% YoY; U.S. revenue +17%; H1 sales $4.4M, +20%.","Gross margin improved to 76% from 56% on pricing, mix, contract manufacturing.","Net loss $4.8M incl. $1.7M non-cash warrant expense; cash $3.9M at June 30.","Raised ~$12.7M gross proceeds from June offering and July financing/warrant exercises.","Appointed Mike McCormick CEO effective June 30; FDA pre-sub for Aquadex label to 5kg."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032838","json":"https://secwatch.observer/filing/0001140361-26-032838.json","markdown":"https://secwatch.observer/filing/0001140361-26-032838.md","text":"https://secwatch.observer/filing/0001140361-26-032838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126032838/0001140361-26-032838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126032838/ef20080204_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:40:08.850324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}